

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported)**  
September 12, 2014

---

**AKEBIA THERAPEUTICS, INC.**

(Exact name of registrant as specified in charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36352**  
(Commission File Number)

**20-8756903**  
(I.R.S. Employer  
Identification No.)

**245 First Street, Suite 1100, Cambridge, Massachusetts 02142**  
(Address of Principal Executive Offices, including Zip Code)

**(617) 871-2098**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Election of Directors*

On September 12, 2014, the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, elected Ronald C. Renaud, Jr. as a Class I Director, effective as of September 12, 2014. Mr. Renaud’s initial term will last until the 2015 annual meeting of stockholders. At the time of filing, the Board had not yet determined the committees to which Mr. Renaud will be assigned.

Consistent with the Company’s director compensation policy, which was previously described in the Company’s 424(b) prospectus filed on March 21, 2014, Mr. Renaud will be eligible to receive certain cash and equity compensation. Mr. Renaud will also enter into a customary indemnification agreement with the Company.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Akebia Therapeutics, Inc. dated September 15, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKEBIA THERAPEUTICS, INC.**

By: /s/ JOHN P. BUTLER

John P. Butler

President and Chief Executive Officer

Date: September 15, 2014

**EXHIBIT INDEX**

**Exhibit No.**

**Description**

---

99.1 Press Release of Akebia Therapeutics, Inc. dated September 15, 2014



**Akebia Therapeutics, Inc.**  
245 First Street, Suite 1100  
Cambridge, MA 02142  
T: +1 617.871.2098 F: +1 617.871.2099  
www.akebia.com

---

**FOR IMMEDIATE RELEASE**

**Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors**

**Cambridge, Mass. – September 15, 2014** – Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia’s Board of Directors.

“As a prominent and well-respected industry veteran and visionary, Ron brings significant experience and tremendous value to the company,” said Muneer A. Satter, Chairman of Akebia’s Board of Directors. “Akebia continues to progress AKB-6548 toward late-stage clinical development as a treatment for anemia related to chronic kidney disease, while advancing earlier stage HIF compounds with the potential to treat a broad range of serious diseases. We welcome Ron to the Board and look forward to his contributions in the critical and exciting months that lie ahead for the company.”

Mr. Renaud served as President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc. from October 2010 until the company’s recent acquisition by Merck. Prior to that, Mr. Renaud served in several key roles at Idenix including Chief Financial Officer, Treasurer and Chief Business Officer. Before joining Idenix, Mr. Renaud served as Senior Vice President and Chief Financial Officer of Keryx Biopharmaceuticals, Inc. Previously, Mr. Renaud was also a Senior Research Analyst and Global Sector Coordinator for JP Morgan Securities, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. Mr. Renaud also spent more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.

“I am delighted to join Akebia’s Board, particularly at this exciting time for the company. Akebia continues to build momentum as it approaches the Phase 2b data readout for AKB-6548 later this year and prepares to embark on a Phase 3 development program in 2015,” said Mr. Renaud. “The potential opportunities for a once-daily, oral treatment option that could safely and effectively treat patients with chronic kidney disease impacted by anemia are significant. A new approach to address this serious medical condition would represent not only a paradigm shift, but a true scientific and medical advancement.”

AKB-6548 is currently in Phase 2b development for the treatment of anemia related to chronic kidney disease in patients who are not dependent on dialysis, with results expected in the fourth quarter of 2014.

**About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on harnessing the potential of hypoxia-inducible factor (HIF) biology

to develop and commercialize novel, proprietary therapeutics to treat kidney disease. Akebia's lead clinical program, AKB-6548, is a once-daily, oral therapy currently in Phase 2b clinical development for the treatment of anemia related to chronic kidney disease, a serious medical condition that leads to increased morbidity and mortality if left untreated. For more information on Akebia, please visit [www.akebia.com](http://www.akebia.com).

#### **Forward-Looking Statements**

This press release includes forward-looking statements. Such forward-looking statements include those about Akebia's strategy, future plans and prospects, including statements regarding the potential indications and benefits of AKB-6548 and Akebia's pre-clinical compounds, the expected timing of the announcement of data from the Phase 2b study and the commencement of the Phase 3 study, and the progress of Akebia's early stage research program. The words "anticipate," "appear," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the ability of Akebia to successfully complete the clinical development of AKB-6548 or any other product candidate; the funding required to develop Akebia's product candidates and operate the Company, and the actual expenses associated therewith; the content of decisions made by the FDA and other regulatory authorities; the actual time it takes to complete the Phase 2b study and analyze the data; the success of competitors in developing product candidates for diseases for which Akebia is currently developing its product candidates; and Akebia's ability to obtain, maintain and enforce patent and other intellectual property protection for AKB-6548 or any other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and other filings that Akebia may make with the Securities and Exchange Commission in the future. Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

#### **Contact:**

#### **Investors:**

Akebia Therapeutics, Inc.  
Nicole P. Jones, +1-617-871-1210  
Senior Director, Investor Relations and Corporate Communications  
[njones@akebia.com](mailto:njones@akebia.com)

#### **Media:**

Feinstein Kean Healthcare  
Liz Falcone, +1-617-761-6727  
[liz.falcone@fkhealth.com](mailto:liz.falcone@fkhealth.com)

###